Innate Pharma S.A. Reports Number of Shares and Voting Rights as of December 18, 2025

Innate Pharma S.A. has released its total number of outstanding shares and voting rights as of December 18, 2025. The company reported 92,197,823 ordinary shares, 6,324 Preferred Shares 2016, and 7,581 Preferred Shares 2017. The total number of theoretical voting rights is 92,962,943, and the total number of exercisable voting rights is 92,944,368. The report also provides an "About Innate Pharma" section, describing the company as a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients, with a portfolio including IPH4502, lacutamab, and monalizumab. It mentions collaborations with Sanofi and AstraZeneca, and its listings on Euronext Paris and Nasdaq. The filing includes a disclaimer on forward-looking statements and risk factors, as typically found in SEC filings.